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Cohort B Trial (A Clinical Evaluation of the Bioabsorbable
Everolimus Eluting Coronary Stent System in the Treatment of
Patients With De Novo Native Coronary Artery Lesions)Yoshinobu Onuma, MD,* Patrick W. Serruys, MD, PHD,* Takashi Muramatsu, MD, PHD,* Shimpei Nakatani, MD,*
Robert-Jan van Geuns, MD, PHD,* Bernard de Bruyne, MD, PHD,y Dariusz Dudek, MD,z Evald Christiansen, MD,x
Pieter C. Smits, MD, PHD,k Bernard Chevalier, MD,{ Dougal McClean, MD,# Jacques Koolen, MD, PHD,**
Stephan Windecker, MD,yy Robert Whitbourn, MD,zz Ian Meredith, MD, PHD,xx Hector M. Garcia-Garcia, MD, PHD,kk
Susan Veldhof, RN,{{ Richard Rapoza, PHD,## John A. Ormiston, MBCHB, PHD***ABSTRACTOBJECTIVES This study sought to describe the frequency and clinical impact of acute scaffold disruption and late strut
discontinuity of the second-generation Absorb bioresorbable polymeric vascular scaffolds (Absorb BVS, Abbott Vascular,
Santa Clara, California) in the ABSORB (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in
the Treatment of Patients With De Novo Native Coronary Artery Lesions) cohort B study by optical coherence tomography
(OCT) post-procedure and at 6, 12, 24, and 36 months.
BACKGROUND Fully bioresorbable scaffolds are a novel approach to treatment for coronary narrowing that provides
transient vessel support with drug delivery capability without the long-term limitations of metallic drug-eluting stents.
However, a potential drawback of the bioresorbable scaffold is the potential for disruption of the strut network when over-
expanded. Conversely, the structural discontinuity of the polymeric struts at a late stage is a biologically programmed fate of
the scaffold during the course of bioresorption.
METHODS The ABSORB cohort B trial is a multicenter single-arm trial assessing the safety and performance of the Absorb
BVS in the treatment of 101 patients with de novo native coronary artery lesions. The current analysis included 51 patients with
143 OCT pullbacks who underwent OCT at baseline and follow-up. The presence of acute disruption or late discontinuities was
diagnosed by the presence on OCT of stacked, overhung struts or isolated intraluminal struts disconnected from the expected
circularity of the device.
RESULTS Of 51 patients with OCT imaging post-procedure, acute scaffold disruption was observed in 2 patients (3.9%),
which could be related to overexpansion of the scaffold at the time of implantation. One patient had a target lesion revas-
cularization that was presumably related to the disruption. Of 49 patients without acute disruption, late discontinuities were
observed in 21 patients. There were no major adverse cardiac events associated with this ﬁnding except for 1 patient who had a
non-ischemia-driven target lesion revascularization.
CONCLUSIONS Acute scaffold disruption is a rare iatrogenic phenomenon that has been anecdotally associated with
anginal symptoms, whereas late strut discontinuity is observed in approximately 40% of patients and could be viewed as
a serendipitous OCT ﬁnding of a normal bioresorption process without clinical implications. (ABSORB Clinical Investigation,
Cohort B [ABSORB B]; NCT00856856) (J Am Coll Cardiol Intv 2014;7:1400–11) © 2014 by the American College of Cardiology
Foundation.
AB BR E V I A T I O N S
AND ACRONYM S
BVS = bioresorbable polymeric
vascular scaffolds
Dmax = maximum diameter
IVUS = intravascular
ultrasound
OCT = optical coherence
tomography
QCA = quantitative coronary
angiography
TLR = target lesion
revascularization
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1401F ully bioresorbable scaffolds are a novelapproach for treatment of coronary narrowingthat provides transient vessel support with
drug delivery capability without the long-term limita-
tions of metallic drug-eluting stents, such as perma-
nent caging with either outward bulging
(evagination) of the luminal wall outside of the
“cage,” or intracage neoatherosclerosis (1,2). By
freeing the coronary artery from metallic caging, the
vessel thereby recovers its pulsatility, and vasomo-
tion becomes again responsive without any
constraint to the biochemical milieu, the endothelial
shear stress, and the physiological cyclic strain (3,4).
The technology has the potential to overcome many
of the safety concerns associated with metallic drug-
eluting stents and could possibly even provide
further clinical beneﬁt (5).
In the ABSORB (A Clinical Evaluation of the Bio-
absorbable Everolimus Eluting Coronary Stent System
in the Treatment of Patients With De Novo Native
Coronary Artery Lesions) cohort A trial, the ﬁrst
generation of the Absorb everolimus-eluting fully
bioresorbable polymeric vascular scaffolds (Absorb
BVS, Abbott Vascular, Santa Clara, California) showed
a low event rate with a late lumen enlargement from 6
months to 2 years. At 5 years, the absence of metallic
material allowed the noninvasive anatomical as well
as functional assessment by multislice computed
tomography of arteries previously treated with a
bioresorbable scaffold (4,6,7). In the subsequent
ABSORB cohort B trial, the second generation of the
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graphic late loss was 0.27  0.32 mm, with an
unchanged scaffold area. In addition, vaso-
motion induced by ergonovine and acetyl-
choline followed by intracoronary nitrate
became detectable again, suggesting that the
scaffolds mechanical integrity had subsided.
At 24-month follow-up, the angiographic late
loss remained stable (0.27  0.20 mm) with a
late enlargement of the scaffold that
compensated for the neointimal growth as detected by
OCT (10–12).
However, a potential drawback of this new
technology is the risk for disruption of the strut
network when it is overexpanded. Historically, the
phenomenon was documented for the ﬁrst time in
an anecdotal case from the ABSORB cohort A trial. A
3.0-mm scaffold was overexpanded with a 3.5-mm
balloon, resulting in scaffold disruption as docu-
mented by OCT (7). Due to the recurrence of anginal
symptoms at 40 days, this patient underwent repeat
revascularization despite an angiographically non-
signiﬁcant stenosis by quantitative coronary angi-
ography (QCA) (diameter stenosis of 42%) (13). It is
important that this acute mechanical disruption, is
distinguished from the structural discontinuity of
the polymeric struts at a later stage, a biologically
programmed process during the course of bio-
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1402The purpose of the present report therefore is to
describe the frequency and clinical impact of acute
scaffold disruption and late strut discontinuity of
the second-generation Absorb BVS in the ABSORB
cohort B study. The frequency and impact are docu-
mented in a serial or nonserial manner by OCT post-
procedure and at 6, 12, 24, and 36 months.
METHODS
STUDY POPULATION. The ABSORB cohort B trial is a
multicenter single-arm trial assessing the safety and
performance of the second-generation Absorb BVS in
the treatment of 101 patients with a maximum of 2 de
novo native coronary artery lesions. The inclusion
and exclusion criteria have been described previously
(8,12). The ﬁrst 45 patients (B1) had an invasive im-
aging follow-up at 6 and 24 months, whereas the
latter 56 patients (B2) had an imaging follow-up at 12
months and at 36 months.
The current analysis included 51 patients who un-
derwent OCT at baseline as an optional investigation.
The details of the follow-up are presented in Online
Figure 1. In total, the analysis included 143 OCT
pullbacks performed at baseline and follow-up. The
details of the study device and study procedure are
described in the Online Appendix.
OPTICAL COHERENCE TOMOGRAPHY. As an optional
investigation, intravascular OCT imaging using either
time-domain OCT (M3 system, LightLab Imaging,
Westford, Massachusetts) or frequency-domain OCT
(C7XR system, LightLab Imaging) was performed at
baseline and at follow-up (15–19). The OCT measure-
ments were performed with proprietary software for
ofﬂine analysis (LightLab Imaging). To search for
the presence of scaffold disruption, the analysis of
continuous cross sections was performed in all frames
within the treated segment. The main quantitative
measurements (strut core area, strut area, lumen
area, scaffold area, incomplete scaffold apposition
area, and neointimal area) required different analysis
rules than metallic stents (8,9,12,20). The thickness of
the neointimal coverage was measured for every strut
between the abluminal side of the strut core and the
lumen. Because the strut thickness is approximately
150 mm, the strut was considered as covered when-
ever the thickness of the coverage was above this
threshold value (8,12).
DEFINITION OF ACUTE SCAFFOLD DISRUPTION OR
LATE DISCONTINUITY ON OCT. Ex vivo experiments
were performed to identify OCT ﬁndings of disrupted
struts. In a silicon phantom with a diameter of
3.5 mm, a 3.0-mm Absorb BVS (maximal labeleddiameter expansion of 3.5 mm) was deployed and
expanded with a 4.0-mm compliant balloon (21).
After disrupting the scaffold, OCT pullback was
performed and analyzed (Figure 1). Acute (peri-
procedural) structural scaffold disruption or late strut
discontinuities were diagnosed by at least 1 of the
following: 1) if 2 struts overhung each other in the
same angular sector of the lumen perimeter, without
close contact (overhung strut) or with contact
(stacked strut) in at least 1 cross section; or 2) if there
was isolated (malapposed) struts that could not be
integrated in the expected circularity of the device in
at least 1 cross section. “Isolated strut” was deﬁned
as a strut located at a distance from the vessel wall
(>1/3 of span between the center of gravity and the
luminal border) (8,12,21).
If acute scaffold disruption was persistently
observed at follow-up, the case was classiﬁed as
persistent scaffold disruption. Late discontinuity at
follow-up was diagnosed when no initial procedural
scaffold disruption could be documented post-
procedure. In the case of iterative follow-up, late
discontinuities could be classiﬁed as resolved or
persistent (Table 1). Using the new criteria, the OCT
image was reanalyzed for the presence of acute
disruption or late discontinuities. The details of 3-
dimensional OCT analysis, IVUS grayscale analysis,
and deﬁnition of clinical events are described in the
Online Appendix.
STATISTICAL ANALYSIS. Continuous variables are
presented as mean  SD, whereas categorical vari-
ables are expressed as percent. Categorical variables
were compared using Pearson chi-square test or
Fisher exact test and continuous variables were
compared using F test for analysis of variance. As no
formal hypothesis testing was planned for assessing
the success of the study, no statistical adjustment
was applied. The p values presented are exploratory
analyses only and therefore should be interpreted
cautiously. Statistical analysis was performed with
SPSS (version 20 for Macintosh, SPSS Inc., Chicago,
Illinois).
RESULTS
Baseline characteristics are presented in Online
Table 1. All patients received 1 Absorb scaffold
except for 1 patient who received 2. Post-dilation was
performed in 57% of lesions.
ACUTE PROCEDURAL SCAFFOLD DISRUPTION AT
BASELINE. Of 51 patients with OCT imaging post-
procedure (52 scaffolded lesions), acute scaffold
disruption was observed in 2 patients (3.9%). Table 2
FIGURE 1 OCT Criteria to Diagnose Acute Scaffold Disruption (Phantom Assessment)
In a silicon phantom, a 3.0-mm Absorb BVS scaffold was disrupted through inﬂation of a semicompliant balloon up to 4.3 mm in diameter. Optical coherence tomography
(OCT) showed the following: more than 2 struts in the same angular sector with close contact (2 struts stacked) (A) or without any contact (overhung struts) (B).
The other presentation of disrupted scaffold is the detection of an isolated malapposed strut located at the center of the lumen with loss of circularity of the scaffold (C).
The distance from the abluminal side of the strut to the luminal border should be more than one-third of the distance from the center of gravity to the lumen border
in the corresponding angular sector.
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1403tabulates the details of the procedures and imaging
by OCT, IVUS, and QCA. Scaffold disruption at base-
line was detectable on IVUS in 1 of these 2 cases.
Notably, 1 patient had a target lesion revasculari-
zation (TLR) presumably associated with the acute
disruption and its worsening at 1 month. In this case
(Figure 2), an Absorb BVS 3.0 mm  18 mm scaffold
was implanted in an obtuse marginal branch with
a reference diameter of 3.26 mm (13). After post-
dilation with a 3.25-mm noncompliant balloon atTABLE 1 Classiﬁcation of OCT Findings
Etiology Post-Procedure
Scaffold disruption Procedure-related
 Stacked struts
 Overhung struts
 Isolated intralum
strut(s)
Scaffold discontinuities Resorption-related NA
Artifacts such as nonuniform rotational deformation and noncoaxial positioning of the ca
when serial OCT is available (baseline/follow-up). If serial imaging cannot determine th
procedural disruption etiology, whereas the presence of a circular strut conﬁguration
diagnostic procedure at follow-up, which either aggravates or creates the disruption. ‡Is
with homogenous tissue.
NA ¼ not applicable; OCT ¼ optical coherence tomography.24 atm, malapposition remained at the proximal part
of the scaffold on OCT. To correct the malapposition,
an additional post-dilation was performed with a
compliant 3.5-mm balloon at 16 atm (expected diam-
eter, approximately 4.0 mm). The repeat OCT and
IVUS demonstrated acute scaffold disruption in the
scaffolded segment. At 1 month, the patient experi-
enced 5 episodes of recurrent angina at rest. Despite
the fact that the exercise tolerance test was negative,
the patient underwent recatheterization because ofTime of OCT Observation
Late
Late persistent*/Late procedural†
 Stacked struts with/without coverage, with/without malapposition
 Overhung struts with/without coverage, with/without malapposition
inal  Isolated malapposed struts with‡/without coverage
Late acquired*
 Stacked/overhung/isolated or intraluminal strut(s) with or
without coverage or malapposition
theter should be excluded with caution (21). *Late persistent or late acquired can be only diagnosed
e etiology, the absence of a circular strut conﬁguration at a late imaging time point may support a
may support the etiology of a resorption-related discontinuity. †Late procedural is related to the
olated malapposed struts can be detected as neointimal bridge where the struts are thickly covered
TABLE 2 Details of Patients With Acute Disruption
Case #1 Case #2
Sex Male Male
Age, yrs 78 83
Pre-procedural QCA
Minimal lumen
diameter, mm
1.61 0.87
Reference vessel
diameter, mm
3.26 2.24
Angulation,  35.54 2.97
Curvature, cm-1 0.04 0.005
Procedural details
Size of implanted
BVS, mm
3.0  18 3.0  18
Post-dilation Performed Performed
Size of post-dilation
balloon, mm
3.5  9 mm
(compliant)
3.0  10
(noncompliant)
Maximal pressure at
post-dilation, atm
16 24
Expected diameter of
balloon at maximal
pressure according
to the chart,* mm
>3.96 >3.22
Maximal balloon
diameter by QCA, mm
3.87 2.98
OCT ﬁndings at baselines
Total CS with strut
disruption
6 5
CS with isolated struts 1 1
CS with overhung struts 5 4
CS with stacked struts 0 0
Minimal lumen area, mm 5.82 3.59
Minimal scaffold
area, mm2
7.83 5.23
IVUS at baselines
Visibility of strut
disruption on IVUS
Yes No
Minimal lumen
area, mm2
6.04 4.68
Minimal scaffold
area, mm2
6.04 4.68
QCA at baselines
Percent of diameter
stenosis, %
20 1.3
Minimal lumen
diameter, mm
2.7 1.94
Timing of 1st follow-up 1 months 6 months
OCT ﬁndings at
1st follow-up
Total CS with strut
disruptions
22 8
CS with isolated struts 2 4
CS with overhang struts 20 6
CS with stacked struts 1 0
Minimal lumen area, mm2 NA† 4.82
Minimal scaffold
area, mm2
NA† 6.01
Continued in the next column
TABLE 2 Continued
Case #1 Case #2
IVUS at 1st follow-up
Visibility of strut
disruption on IVUS
Yes No
Minimal lumen
area, mm2
5.23 4.21
Minimal scaffold
area, mm2
5.23 4.21
QCA at 1st follow-up
Percent of
diameter stenosis, %
23 23
Minimal lumen
diameter, mm
2.47 1.84
Late loss, mm 0.23 0.1
OCT ﬁndings at 2 yrs
Total CS with strut
disruptions
0 25
CS with isolated struts 0 14
CS with overhang struts 0 12
CS with stacked struts 0 0
Minimal lumen area, mm2 NA‡ 5.15
Minimal scaffold
area, mm2
NA‡ 7.46
Findings in
3-dimensional
reconstruction
NA‡ Tissue arch
IVUS at 2 yrs
Visibility of strut
disruption on IVUS
No Yes
Minimal lumen
area, mm2
NA 5.87
Minimal scaffold
area, mm2
NA 6.15
QCA at 2 yrs
Percent of
diameter stenosis, %
14.5 25.5
Minimal lumen
diameter, mm2
2.74 1.8
Late loss, mm –0.4 0.11
Clinical events up to
2 yrs
Non-ischemia-driven
target lesion
revascularization
None
Values are n unless otherwise indicated. *The balloon diameter at maximal pres-
sure is in a chart provided by the balloon manufacturer. †The quantitative
assessment was not performed because in many cross sections, the complete
luminal border was not visualized. ‡The quantitative assessment was not per-
formed because the segment was covered by a metallic stent after non-ischemia-
driven revascularization.
CS ¼ cross section(s); IVUS ¼ intravascular ultrasound; NA ¼ not available;
QCA ¼ quantitative coronary angiography.
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1404persisting symptoms. The angiography revealed a
patent scaffold segment with a TIMI (Thrombolysis In
Myocardial Infarction) ﬂow grade 3; however, OCT,
compared with baseline images, showed a deteriora-
tion of scaffold disruption. There was no tissueobserved around the struts. A metallic Xience V stent
(Abbott Vascular) was placed inside the Absorb scaf-
fold, which eliminated the symptoms. After this
nonischemic TLR, there was a rise in troponin (0.09
ml/g with an upper limit of normal of 0.03 ml/g), which
would be adjudicated as a non–Q-wave myocardial
infarction according to the Academic Research Con-
sortium deﬁnition.
In the second case, a 3.0-mm scaffold was implan-
ted in a small vessel with a reference vessel diameter
FIGURE 2 A Case of Acute Disruption
Each series of framed illustrations (yellow, green, blue, and orange) represents the observation at different time points (before post-dilation, after post-dilation, at
1 month [M] and at 2 years [Y]). An Absorb BVS 3.0 mm  18 mm scaffold was implanted in an obtuse marginal branch (A) (pre-procedural angiography) with a reference
diameter of 3.26 mm. After the ﬁrst post-dilation by a 3.25-mm noncompliant balloon at 24 atm (B), malapposition remained at the proximal part of the scaffold on
optical coherence tomography (OCT) (C, D). To correct the malapposition, an additional post-dilation was performed with a compliant 3.5-mm balloon at 16 atm
(expected diameter, approximately 4.0 mm) (E). The angiographic result was successful (F) but the post-procedural OCT (G and I) and intravascular ultrasound (IVUS)
demonstrated acute strut disruption (H and J) in the scaffolded segment. Presence of a long strut extending greater than 90 degree suggests overexpansion of scaffold
(K). On both OCT and IVUS, isolated intraluminal struts (white arrow: OCT in G and IVUS in H) and overhung struts (white arrow: OCT in I and IVUS in J) were observed. At
1 month, the patient had 5 episodes of recurrent angina at rest. The angiography (L) revealed a patent scaffold segment with a TIMI (Thrombolysis In Myocardial
Infarction) ﬂow grade 3; however, OCT (M, N, P) showed a deterioration of strut discontinuity (white arrows: isolated intraluminal or overhung struts). In the corre-
sponding IVUS frames (O and Q), the disrupted struts were also visible. A metallic Xience V stent was placed inside the Absorb BVS scaffold (R). Post-target lesion
revascularization OCT (S) showed the metallic struts, with shadows behind (blue arrows), are located inside of a polymeric strut (white arrow). At 2 years, the planned
repeat angiography showed a patent stented segment (T), whereas OCT (U) showed in some cross sections the presence of covered polymeric struts (white arrow) inside
the metallic struts (light blue arrow).
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1405of 2.24 mm followed by a post-dilation with a 3.0-mm
noncompliant balloon at 24 atm. Immediately
after procedure, overhung struts were observed on
OCT at baseline in 5 cross sections (Figure 3). Accord-
ing to the protocol, this asymptomatic patient
underwent repeat angiography at 6 months with
IVUS and OCT imaging. After the IVUS acquisition,
the operator experienced difﬁculty recrossing the
scaffold segment with the OCT catheter. After rewiring
the scaffolded vessel, OCT was successfully acquired,which demonstrated extremely malapposed struts
close to the OCT catheter (see the noncircularity of
struts). The irregularity of the strut structure might
have been caused by advancing the wire outside of
the scaffold and pushing the OCT catheter under
the abluminal side of the struts. At 2-year imaging
follow-up, OCT revealed detached struts densely
encapsulated with homogeneous tissue, forming
an arch attached proximally and distally to the
vessel wall. On IVUS, it was documented as a
FIGURE 3 An Example of Acute Disruption
Each series of framed illustrations (yellow, green, and blue) represents the observation at different time points (post-procedure, at 6 months, and at 2 years). An Absorb
BVS scaffold was implanted in a small circumﬂex (reference vessel diameter 2.42 mm) (A) followed by post-dilation with a 3.0-mm noncompliant balloon at a maximal
pressure of 24 atm (B). Post-procedural OCT detected overhung struts or isolated struts in 5 cross sections (C), which were not detected by IVUS (D). At 6-month follow-
up, the patient underwent repeat angiography that revealed low angiographic late loss of 0.10 mm (E). According to the protocol, IVUS (F) and OCT were performed.
IVUS did not detect any abnormality (G, H). After IVUS, the operator experienced difﬁculty crossing the scaffolded segment with the OCT catheter (I). After rewiring the
scaffolded segment, OCT was successfully acquired and showed isolated struts close to the OCT catheter with loss of circularity of the scaffold (J, K, L: corresponding
frames with G and H). On 3-dimensional OCT, it was evident that 1 ring of the scaffold was detached from the vessel wall (M) and divided the coronary ﬂow (N)
(endoscopic view). The late disruption of the scaffold might have been induced by advancing the wire outside of the scaffold, pushing the OCT catheter under the
abluminal side of the struts during the ﬁrst crossing attempt. Despite the abnormal OCT ﬁndings, the patient remained asymptomatic up to 2 years. At 2-year angio-
graphic follow-up (O), OCT revealed detached struts (P, R, T), which were fully covered by thick homogeneous tissue extending as an endoluminal arch connected
proximally and distally to the vessel wall (3-dimensional) (U, V). On IVUS, it was documented as a “dissection” in a scaffold segment (Q, S). P, R, and Q, S are the
corresponding frames on OCT and IVUS, respectively. Abbreviations as in Figure 2.
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1406dissection in the scaffold segment. Despite the
abnormal imaging ﬁndings, the patient remains
asymptomatic to date.
LATE STRUT DISCONTINUITIES AT FOLLOW-UP.
Follow-up OCT images were obtained in all but 2 pa-
tients (at 6 months, 1 year, 2 years, or 3 years) (Online
Figure 1). Of 50 scaffolded lesions (49 patients)
without acute scaffold disruption, late acquired
structural discontinuity was observed in 21 scaffolds
(n ¼ 21, 42%). The cases are detailed in Online Table 2and Figure 4. There were no differences in baseline
characteristics between patients with or without late
discontinuities except for the pre-procedural minimal
lumen diameter and diameter stenosis, which could
be a play of chance. On IVUS, late discontinuities
were detected only in 3 cases.
In the series with 6- and 24-month follow-up, late
discontinuities were observed in 3 cases at 6 months
and were persistently observed at the second follow-
up at 24 months (Online Figure 2). In 8 cases, late
discontinuities were observed only at 2 years.
FIGURE 4 Late Discontinuities
(A) The development of late discontinuities is shown; each line represents a scaffold with late discontinuities at various time points of follow-up
(post-procedure, 6, 12, 24, and 36 months). Open circles indicate OCT investigation without late strut discontinuities, whereas solid circles
represent OCT observation with late discontinuities at that time point. Framed illustrations in blue (B, C, D) correspond to scaffolds with
resolution at 36 months of late acquired discontinuity originally detected at 12 months. Framed illustrations in red (D, E, F) correspond to a
scaffold with persistent (at 36 months) late discontinuities detected at 12 months. In both cases, the stacked struts were already covered at
12 months. BL ¼ baseline, SB ¼ side-branch; other abbreviations as in Figures 1 and 2.
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1407In the series with 1- and 3-year follow-up, late
structural discontinuities were observed at 1 year in 8
cases. Two discontinuities were persistently observed
in serial OCT images at 3 years, whereas in 3 cases,
discontinuities were resolved at 3 years. In 2 cases, no
follow-up was performed after 1 year, so the out-
comes of these discontinuities remained unknown.
One patient underwent unscheduled OCT at 2 years,
revealing persistent discontinuities. Two scaffolds
had late structural discontinuities only at 3 years.
Figure 4 illustrates the complex timing and outcome
of these serial or nonserial investigations.
There were no events associated with these late
discontinuities observed on OCT at follow-up except
for 1 patient who underwent a non-ischemia-driven
repeat TLR (Online Figure 3). The 45-year-old man
received a 3.0 mm  18 mm Absorb BVS scaffold in
the mid–left anterior descending artery. Post-
procedural OCT did not show malapposition. At
1 year, the patient underwent a planned repeatangiography, which showed an enlargement of the
lumen. OCT showed late discontinuity with malap-
posed overhanging struts over a length of 4 mm. Due
to the pronounced malapposition, clopidogrel treat-
ment was continued after 1 year. The patient had
stable angina of Canadian Cardiovascular Society
class 2 to 3 and underwent a repeat angiography on
day 722. On angiography, the lumen was found to
become ectatic (QCA maximal diameter: 3.6 mm)
without any signiﬁcant stenosis in the scaffolded
segment, whereas on OCT, 1 ring of scaffold showed
persistent discontinuity with malapposition. Despite
the absence of evidence of ischemia, it was thought
that the anginal symptoms were somewhat related to
the malapposition. A 3.0 mm  28 mmmetallic Xience
Prime stent was placed in the scaffolded segment.
After post-dilation with a 3.5-mm balloon, retention
of angiographic contrast medium was observed along
the new stent and diagnosed as malapposed struts on
OCT. The segment was further dilated with a 4.5-mm
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1408balloon. Following the dilation, contrast retention
was resolved.DISCUSSION
The main ﬁndings of the current analysis are
the following: 1) acute disruption induced by the
procedure was observed in 2 of 51 patients (52 pull-
backs, 3.9%), with 1 patient, it was presumably
related to the TLR; 2) late resorption-related discon-
tinuity was observed in 21 patients with 1, presum-
ably nonrelated, non-ischemia-driven TLR; 3) QCA
was unable to detect these structural changes,
whereas IVUS was able to detect some of the major
acute disruptions/late discontinuities (4 of 23 cases).
ACUTE SCAFFOLD DISRUPTION AND SIZING.
Although both acute scaffold disruption and late
discontinuity can be diagnosed as stacked/overhung
struts or isolated struts on OCT, the 2 phenomena
should be categorized differently: 1 as an accidental
occurrence; and 1 as a programmed biological pro-
cess. At the time of implantation, the bioresorption
process does not inﬂuence the mechanical integrity of
the scaffold at all, so that any disrupted struts
observed immediately after the procedure are the
result of a mechanical disruption caused by extreme
overexpansion of the scaffold. The radial force of the
polymeric device is comparable with a metallic scaf-
fold as long as the device is expanded within certain
restricted limits; however, the mechanical force
yields quickly if expanded over the pre-determined
boundary of expansion.
The tensile strength of the poly-L-lactide is 50 to
70 MPa, whereas that of cobalt-chrome alloy or
stainless steel is in the range of 668 to 1,449 MPa.
Percent of elongation at break is 2% to 10 % for poly-L-
lactide, whereas it is more than 40% for cobalt
chromium or stainless steel. The expansion range
of the polymeric device is therefore inherently
limited (12).
The relationship between the diameter of expan-
sion and likelihood of device disruption was investi-
gated ex vivo in 30,000 scaffolds. After inﬂating a
3.0-mm balloon in a phantom, the presence of acute
scaffold disruption was examined. Up to a size of
3.65 mm, no scaffold disruption was observed. How-
ever, when a 3.0-mm scaffold was expanded to 3.70,
3.76, 3.83, and 3.92 mm in diameter, the likelihood
of acute disruption increased by 3%, 24%, 58%, and
80%. The expansion capability is, however, one of
multiple attributes related to the performance of the
scaffold, such as radial strength, vessel support time,
ﬂexibility, fatigue, and acute recoil. To ensure anoptimal performance of the drug-eluting scaffold, the
scaffold should be expanded within its indicated
range, so that the scaffold will not become disrupted
and will still perform as expected. This expansion
capacity should also be maintained during the entire
shelf life of the device. The manufacturer accordingly
recommends the maximal limits of expansion of the
3.0-mm device examined in this study as 3.5 mm.
To prevent overexpansion, it is important to
implant the scaffold in a properly sized vessel using
angiography or intravascular imaging in order to
avoid severe mismatch between the device and
vessel size. In a previously published study, QCA was
used to detect the maximal diameter (Dmax) of the
vessel in the landing zone proximal or distal to
the stenosis. Three vessel-size groups according to
Dmax (small: <2.5 mm, middle: 2.5 to 3.3 mm, large:
>3.3 mm) were investigated by OCT post-procedure.
The small vessel group presented with a higher
percent of lesions with any degree of edge dissections
visually detected on OCT (small: 61.5% vs. middle:
33.3% vs. large: 11.1%; p ¼ 0.05). Lesions with >5% of
incomplete scaffold apposition were signiﬁcantly
higher in the large vessel group with a Dmax >3.3 mm
(7.7% vs. 36.7% vs. 66.7%; p ¼ 0.02). Thus, sizing
according to Dmax seems to be useful in optimizing
the acute OCT outcomes (22).
Although the incidence of acute scaffold disrup-
tion is low (2 cases, 3.9%), 1 of these 2 cases was
associated with a clinical event of non-ischemia-
driven TLR at 1 month, followed by a rise of
troponin after repeat intervention. On OCT, from
baseline to 1 month, more struts became malapposed
and isolated toward the lumen center, suggesting
that the degree of scaffold disruption may have
become worse over time. Although the presence of
ischemia was not proven, the fact that chest pain
vanished after repeat intervention suggests a rela-
tionship between the acute disruption and the
symptoms. This could be due to the vasomotion
disturbance triggered by the intraluminal presence
of struts, or due to small thrombus formation around
the malapposed struts with subsequent emboliza-
tion. Both explanations are hypothetical as objective
proof was not observed. Although ex vivo analysis
showed that the thrombogenicity of polymeric struts
is less than that of bare-metal struts, the possibility
exists that a small thrombus could form around the
isolated and malapposed struts. This is also sug-
gested by 1 of the cases of acute disruption in cohort
A of the ABSORB trial. The patient presented with
chest pain at rest with OCT showing intraluminal
masses with irregular contour around the disrupted
strut (7).
FIGURE 5 Serial Assessment of Late Discontinuities Using Spread-Out-Vessel Graphics
(A to C) The foldout views represent spread-out-vessel graphics created by correlating the longitudinal distance from the distal scaffold edge to the individual struts
detected in a single cross section (abscissa) with on the ordinate the angle where the individual strut was located in the circular cross section with respect to the center of
gravity of the vessel (ordinates). In each cross section (axial resolution of 200 mm), the circumferential length of each individual strut was depicted in an angular fashion.
The resultant graphic represented the scaffolded vessel, as if it had been cut longitudinally along the reference angle and spread out on a ﬂat surface. The spread-out
view post-procedure (A) showed that the scaffold consisted of 19 rings interconnected by 3 links. At 1 year (B) and 3 years (C), mechanical integrity has gradually
subsided and the distal part of the scaffold was starting to show signs of dismantling, along which late discontinuities were observed. At baseline, in the distal edge of
the scaffold (green dotted line in the foldout view), 2-dimensional optical coherence tomography (OCT) (green frame) revealed well apposed struts. At 1 year, in the
distal edge (red dotted line in the foldout view), 2-dimensional OCT (red frame) showed overhung and apposed struts. At 3 years, these struts remained overhung (blue
line in the foldout view, corresponding to 2-dimensional OCT with a blue frame). The phenomenon is considered benign because the struts are mostly covered at 1 and 3
years. Red dots represent the proximal metallic markers.
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1409LATE, RESORPTION-RELATED STRUCTURAL
DISCONTINUITIES. The hydrolysis of polymeric strut
starts immediately after the device comes in contact
with water, whereas the decrease in mechanical
support of the scaffold starts approximately 6 months
after implantation. The process of restenosis is a
time-limited phenomenon due to negative remodel-
ing of the vessel and neointimal hyperplasia inside of
the stent, which occurs 3 to 6 months afterimplantation in the coronary artery. During this time,
the maintenance of the mechanical structure as well
as the elution of everolimus is critical to prevent
restenosis. Beyond this critical period, however, the
mechanical support of the scaffold, as well as the
active neointimal inhibition are no longer necessary,
because the restenosis process is no longer ongoing.
In fact, after 6 months, the polymeric scaffold starts
losing its mechanical integrity and that can lead to
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1410expected late discontinuity. Figure 5 shows the pro-
gression of structural disintegration over time due to
bioresorption. The spread-out view showed that post-
procedure, the scaffold consisted of 19 rings con-
nected to each other with 3 links, as manufactured. As
shown in Figure 5, at 1 year, mechanical integrity had
partially subsided and the distal part of the scaffold
has started to dismantle, which corresponds to late
discontinuities of individual struts. This phenome-
non is considered benign because the struts are
mostly covered at 1 and 3 years.
Among the 21 cases with late strut discontinuity, 20
cases had no clinical consequences during the entire
follow-up. In 1 case, non-ischemia-driven- TLR with a
metallic stent was performed at 2 years to remediate
an abnormal outward bulging of the vessel wall,
resulting in major malapposition and late strut dis-
continuities already detected by OCT at 1-year
follow-up. Although a huge malapposition could in-
crease a risk of scaffold thrombosis, the microscopic
resolution of OCT imaging may have triggered a new
kind of “occulo-OCT” reﬂex because, on angiography,
this was inconspicuous.
SINGLE OR SERIAL OBSERVATION. In the current
analysis, post-procedural OCT was available in all
cases, which enabled us to distinguish the persistent
acute disruption from late discontinuities. Whenever
OCT was not available post-procedure, differentiation
of persistent acute disruption from late discontinu-
ities was speculative (Table 1). Stacked, overhung, or
isolated malapposed struts with circular structure
that were observed later than 6 months, especially
when covered and apposed, could likely be attributed
to late resorption-related discontinuities.
OCT AND IVUS. The current analysis showed that
IVUS is less sensitive than OCT in the detection of
acute strut disruption or late strut discontinuity.
IVUS was able to detect major disruptions or dis-
continuities, but overlooked some disruptions or
could not differentiate them from malapposition
(23). Because acute scaffold disruption could be
associated with anginal symptoms, OCT might be
recommended as an additional diagnostic technique
when the scaffolded vessel angiographically appears
patent, and oversizing and/or overexpansion is
suspected.
IMAGING PROCEDURE AT FOLLOW-UP. The anec-
dotal cases presented in this report highlight the fact
that imaging procedures at follow-up can worsen pre-
existing scaffold disruptions at late follow-up. The
mechanical strength of the device starts to subside
6 months after implantation so that intravascularimaging follow-up occurring later than 6 months
post-implantation has to be performed cautiously.
Introducing a guidewire into the scaffolded segment
should be carried out carefully in cases of known
malapposition post-procedure. The operator should
not reinvestigate the vessel if any resistance in
advancing the imaging device into the scaffolded
segment is experienced.
STUDY LIMITATIONS. The current study has a limited
number of patients who underwent OCT at the
different time points. However, it is the largest series
of patients investigated with serial OCT over a follow-
up period of 3 years. The “snapshot” nature of the
OCT investigations precludes any dynamic interpre-
tation of the ongoing and intended mechanical
dismantling of the scaffold. For instance, the longi-
tudinal polymeric links rather than the rings may be
the ﬁrst structures to degrade and the longitudinal
mechanical stress might be more intense along the
outer epicardial border of the vessel rather than at
the inner myocardial side. These speculations should
be the focus of further preclinical investigations in-
volving other techniques such as a permanently
implanted sono-micrometer. The OCT criteria used in
this analysis (stacked struts or overhung struts) will
not be applicable to the overlapped segment, because
these strut dispositions are normally seen in such
segments.
CONCLUSIONS
Acute scaffold disruptions are rare procedural phe-
nomena that have been anecdotally associated with
angina symptoms, although pathological correlation
between disrupted struts and angina remain elusive.
They can be generally avoided by respecting the
stated expansion limits for each scaffold diameter. In
case of recurrent angina without angiographic ste-
nosis, OCT might be recommended as an additional
diagnostic technique, whereas the imaging follow-up
later than 6 months needs a careful advance of the
imaging device. Late discontinuities as a result of the
expected resorption process are observed in approx-
imately 40% of patients who experienced, at the time
of follow-up, the struts fully covered or embedded in
tissue and should be viewed as a serendipitous OCT
ﬁnding of a normal bioresorption process without
clinical implication.
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